ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study

Study limitation reported by the research below: “Part 2 is the only randomised, controlled portion of the study; Parts 1, 3, and 4 are open-label single-arm designs, which limits the strength of comparative conclusions across the full trial.”

Papers